We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy

By LabMedica International staff writers
Posted on 28 Mar 2025

Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. More...

Due to the wide variation in symptoms between individuals, patients often struggle to obtain an accurate diagnosis. The standard method for diagnosing coeliac disease involves performing a biopsy of the duodenum (the first part of the small intestine). Pathologists then examine the sample under a microscope or on a computer to identify damage to the villi, which are tiny hair-like structures lining the small intestine. Interpreting these biopsies can be challenging, as the changes often appear subtle. Pathologists typically use the Marsh-Oberhuber scale to assess the severity of the condition, ranging from zero (normal villi, indicating a low likelihood of coeliac disease) to four (completely flattened villi, indicating severe disease). New research now shows that a machine learning algorithm was able to accurately determine, in 97 out of 100 cases, whether an individual had coeliac disease based on their biopsy.

This AI tool, developed by scientists at the University of Cambridge (Cambridge, UK), could expedite the diagnosis of coeliac disease, alleviate pressure on strained healthcare systems, and improve diagnoses in developing countries, where there is a significant shortage of pathologists. In research published in The New England Journal of Medicine AI, the Cambridge researchers presented their machine learning algorithm designed to classify biopsy image data. The algorithm was trained on a comprehensive dataset of over 4,000 images obtained from five hospitals, utilizing five different scanners from four different manufacturers. The team also tested their algorithm on an independent dataset of almost 650 images from an unseen source. When compared with the original diagnoses made by pathologists, the model correctly identified the presence or absence of coeliac disease in more than 97 cases out of 100.

The model demonstrated a sensitivity of over 95%, meaning it accurately identified more than 95 out of 100 individuals with coeliac disease. Additionally, it had a specificity of nearly 98%, meaning it correctly identified almost 98 out of 100 individuals without the disease. Previous research by the team has shown that even pathologists can have differing opinions. In one study, when asked to diagnose coeliac disease on a series of 100 slides, more than one in five cases led to disagreements among pathologists. In this new study, the researchers asked four pathologists to review 30 slides and found that a pathologist was just as likely to agree with the AI model as they were with another pathologist.

“This is the first time AI has been shown to diagnose as accurately as an experienced pathologist whether an individual has coeliac or not. Because we trained it on data sets generated under a number of different conditions, we know that it should be able to work in a wide range of settings, where biopsies are processed and imaged differently,” said Dr. Florian Jaeckle, from the Department of Pathology, and a Research Fellow at Hughes Hall, Cambridge. “This is an important step towards speeding up diagnoses and freeing up pathologists’ time to focus on more complex or urgent cases. Our next step is to test the algorithm in a much larger clinical sample, putting us in a position to share this device with the regulator, bringing us nearer to this tool being used in the NHS.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Four-quadrant streaking of fecal samples on chromogenic UTI agar shows various patterns of relative bacterial species abundance. The assorted shapes of the pinkish colonies indicate different E. coli strains. (Photo courtesy of Sokurenko Lab)

Stool Testing Predicts UTI Risk and Guides Antibiotic Selection

Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.